Trifluoromethylphenyl as P2 for ketoamide-based cathepsin S inhibitors
摘要:
The trifluoromethylphenyl P2 motif from previously reported heteroarylnitrile series has been successfully applied for the design and synthesis of highly potent novel ketoamide-based cathepsin S inhibitors. The key in this process is the change of the torsion angle between the P2 phenyl ring and the attached secondary amide by adding a small Cl, F, or Me group at the 2-position. (C) 2010 Elsevier Ltd. All rights reserved.
[EN] AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE<br/>[FR] ANALOGUES D'AMINO-TÉTRAZOLES ET MÉTHODES D'UTILISATION
申请人:ABBOTT LAB
公开号:WO2005111003A1
公开(公告)日:2005-11-24
A compound having Formula (I) or Formula (II) is disclosed as an P2X7 antagonist, wherein A, B, C, Y, Y, Z, m, v, R1, R2, R3, R4, and R5, are as defined in the description. Methods and compositions for treating disease or condition modulated by P2X7 are also disclosed.
Novel Receptor Antagonists and Their Methods of Use
申请人:Chambers J. Laura
公开号:US20080009541A1
公开(公告)日:2008-01-10
The present invention relates to novel oxo-prolinamide derivatives of formula (I) which modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor
and the use of such compounds or pharmaceutical compositions thereof in the treatment of disorders mediated by the P2X7 receptor, for example pain, inflammation and neurodegeneration.
[EN] IMINOTETRAHYDROPYRIMIDINONE DERIVATIVES AS PLASMEPSIN V INHIBITORS<br/>[FR] DÉRIVÉS D'IMINOTÉTRAHYDROPYRIMIDINONE UTILISÉS COMME INHIBITEURS DE PLASMEPSINE V
申请人:UCB BIOPHARMA SPRL
公开号:WO2017089453A1
公开(公告)日:2017-06-01
A series of 2-imino-6-methyltetrahydropyrimidin-4(lH)-one derivatives, substituted in the 6-position by a phenyl moiety which in turn is meta-substituted by an optionally substituted unsaturated fused bicyclic ring system containing at least one nitrogen atom, being selective inhibitors of plasmepsin V activity, are beneficial as pharmaceutical agents, especially in the treatment of malaria.
In one aspect, the invention relates to compounds of formula I:
where R
1-6
are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
The present invention relates to compounds of the formula (I)
or a tautomer or prodrug thereof, or a pharmaceutically acceptable salt of said compound, tautomer or prodrug, wherein:
R
1
, R
2
, R
3
, R
4
and R
5
are each independently selected from H, halo, CN, CF
3
and CONH
2
; compositions containing such compounds and the uses of such compounds as antiparasitic agents.